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Trichomonas vaginalis is the most common nonviral etiology ofsexually transmitted infection (STI) worldwide (1). The
OSOM Trichomonas rapid test (OSOM; Sekisui Diagnostics, San
Diego, CA) is a rapid surrogate to microscopic analysis in symp-
tomatic patients (2), but its performance in low-prevalence STI
populations has been assessed on a limited basis in the literature
(3). OSOM has widespread usage, as accreditation data from the
College of American Pathologists report that over 300 participant
laboratories utilize this assay on an annual basis (4). We sought to
characterize the analytical and clinical performance of OSOM in a
low-prevalence STI population on the basis of a commercial tran-
scription-mediated amplification (TMA) reference.
Results from the performance of OSOM with 1,421 consecu-
tive vaginal saline suspensions were audited from a 4-month in-
terval in a low-prevalence southeasternWisconsin STI population
(5). The concomitant Aptima specimen transport tube from the
health care encounter (98.7% endocervical, 1.3% vaginal), previ-
ously subjected to Chlamydia trachomatis and Neisseria gonor-
rhoeae TMA (Aptima Combo 2 assay; Hologic, San Diego, CA),
was forwarded for retrospective T. vaginalis TMA (Aptima
Trichomonas vaginalis assay; Hologic) evaluation on a TIGRIS
direct tube sampling (DTS) system per the manufacturer’s speci-
fications (6). A previous assessment of T. vaginalis TMA showed
100% molecular concordance between the data from vaginal sa-
line suspension aliquots and endocervical specimens maintained
in Aptima specimen transport tubes (7). In addition, Napierala et
al. (8) have shown equivalent T. vaginalis TMA detection rates
from endocervical swabs and vaginal swabs in our population.
This study was governed by the Wheaton Franciscan Healthcare
Institutional Review Board.
The low-prevalence STI population exhibited TMA detection
rates of 6.4% and 0.6% for C. trachomatis and N. gonorrhoeae,
respectively, while the T. vaginalis TMA detection rate was 4.0%.
On the basis of a T. vaginalis TMA reference standard, the sensi-
tivity and specificity of OSOM were 35.1% and 99.9%, respec-
tively (Table 1). The kappa value for this data set was 0.502 (95%
confidence interval, 0.346 to 0.658), and agreement was 0.973
(95% confidence interval, 0.963 to 0.981).
In an analogous fashion, 98 consecutive tandem vaginal saline
suspensions and endocervical swabs from an increased-preva-
lence STI setting (C. trachomatis TMA detection rate, 11.2%; N.
gonorrhoeae TMA detection rate, 6.1%; setting characterized pre-
viously [7, 9]) were retrospectively analyzed via OSOM and T.
vaginalis TMA, respectively, per the manufacturer’s guidelines (2,
6). Improved concordance between OSOM and T. vaginalis TMA
was observed within this study set, with a 21.4% T. vaginalis TMA
detection rate (Table 2). An increased kappa value of 0.904 (95%
confidence interval, 0.797 to 1.000) was calculated, with agree-
ment of 0.969 (95% confidence interval, 0.907 to 0.992).
Campbell et al. (3) reported 94.7% sensitivity for OSOM com-
pared to microscopy in a population with a 1.9% T. vaginalis
detection rate. Molecular diagnostics did not factor into the de-
termination of the overall T. vaginalis incidence. For a high-prev-
alence population, Huppert and colleagues (10, 11) reported 83 to
90% sensitivity for OSOM. One can hypothesize that the signifi-
cant T. vaginalis TMA/T. vaginalis antigen discordance frequency
in our low-prevalence population is related to organism burden
(12) or to T. vaginalis TMA detection in asymptomatic patients.
However, 56.8% of OSOM-negative/T. vaginalis TMA-positive
data in the low-prevalence population were derived from symp-
tomatic patients (determined by chart review to have pelvic pain,
abdominal pain, vaginal discharge, irritation, or itching). This rate
of symptom incidence did not differ from that for patients yield-
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TABLE 1 Performance of OSOM Trichomonas rapid test and Aptima
Trichomonas vaginalis assay in a low-prevalence STI community
OSOM Trichomonas
rapid test result
No. of specimens with
indicated result by
Aptima Trichomonas
vaginalis assay
Total no. of
specimensPositive Negative
Positive 20 1a 21
Negative 37 1,363 1,400
Total 57 1,364 1,421
a Repeat Aptima Trichomonas vaginalis assay testing yielded a negative result.
TABLE 2 Performance of OSOM Trichomonas rapid test and Aptima
Trichomonas vaginalis assay in an increased-prevalence STI community
OSOM Trichomonas
rapid test result
No. of specimens with
indicated result by
Aptima Trichomonas
vaginalis assay
Total no. of
specimensPositive Negative
Positive 18 0 18
Negative 3 77 80
Total 21 77 98
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ing positive OSOM and T. vaginalis TMA results (P 0.17; Table
3). Moreover, symptomatic status did not impact concordant and
discordant OSOM/T. vaginalis TMA frequencies in the increased-
prevalence population (P 0.54).
It has been documented that up to 70% of infections with T.
vaginalis are asymptomatic (13). Detection of subclinical
trichomoniasis is important, as studies have demonstrated persis-
tent indolent infection via laboratory detection of the agent fol-
lowing previously negative results in the face of sexual abstinence
(14, 15). In further support of this paradigm, 27% of the 37 pa-
tients with OSOM-negative/retrospective T. vaginalis TMA-posi-
tive results in our low-prevalence population returned for clinical
evaluation of an STI (data not shown). In conclusion, poor reli-
ability of OSOM in a low-prevalence population combined with
the inability to detect the organism in a significant proportion of
symptomatic patients may warrant consideration of T. vaginalis
TMA for accurate laboratory diagnosis of this protozoan.
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TABLE 3 Symptomatic status of Aptima Trichomonas vaginalis assay-
positive patients from low- and increased-prevalence STI communities
stratified by OSOM Trichomonas rapid test result
OSOM Trichomonas
rapid test result
No. (%) of patients positive by Aptima
Trichomonas vaginalis assay exhibiting
symptoms
Low-prevalence
community
Increased-prevalence
community
Positive 15 (75.0) 16 (88.9)
Negative 21 (56.8)a 3 (100.0)b
a P 0.17, versus those with positive OSOM result; significance test of proportions.
b P 0.54, versus those with positive OSOM result; significance test of proportions.
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